FULC
Price:
$3.26
Market Cap:
$203.43M
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmon...[Read more]
Industry
Biotechnology
IPO Date
2019-07-18
Stock Exchange
NASDAQ
Ticker
FULC
According to Fulcrum Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -8.28%. This represents a change of 169.79% compared to the average of -3.07% of the last 4 quarters.
The mean historical ROE of Fulcrum Therapeutics, Inc. over the last ten years is -296.30%. The current -8.28% ROE has changed -97.21% with respect to the historical average. Over the past ten years (40 quarters), FULC's ROE was at its highest in in the June 2024 quarter at 20.24%. The ROE was at its lowest in in the March 2018 quarter at -524.96%.
Average
-296.30%
Median
-53.09%
Minimum
-1737.07%
Maximum
-37.03%
Discovering the peaks and valleys of Fulcrum Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 111.70%
Maximum Annual ROE = -37.03%
Minimum Annual Increase = -97.53%
Minimum Annual ROE = -1737.07%
Year | ROE | Change |
---|---|---|
2023 | -41.39% | -22.05% |
2022 | -53.09% | 43.38% |
2021 | -37.03% | -48.50% |
2020 | -71.91% | -20.79% |
2019 | -90.77% | 111.70% |
2018 | -42.88% | -97.53% |
The current ROE of Fulcrum Therapeutics, Inc. (FULC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-43.84%
5-year avg
-58.84%
10-year avg
-296.30%
Fulcrum Therapeutics, Inc.’s ROE is greater than RAPT Therapeutics, Inc. (-86.04%), greater than Mirum Pharmaceuticals, Inc. (-43.47%), less than BeyondSpring Inc. (54.63%), greater than Stoke Therapeutics, Inc. (-57.89%), less than Phathom Pharmaceuticals, Inc. (251.33%),
Company | ROE | Market cap |
---|---|---|
-86.04% | $79.23M | |
-43.47% | $1.93B | |
54.63% | $86.32M | |
-57.89% | $689.69M | |
251.33% | $1.29B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fulcrum Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Fulcrum Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Fulcrum Therapeutics, Inc.'s ROE?
How is the ROE calculated for Fulcrum Therapeutics, Inc. (FULC)?
What is the highest ROE for Fulcrum Therapeutics, Inc. (FULC)?
What is the 3-year average ROE for Fulcrum Therapeutics, Inc. (FULC)?
What is the 5-year average ROE for Fulcrum Therapeutics, Inc. (FULC)?
How does the current ROE for Fulcrum Therapeutics, Inc. (FULC) compare to its historical average?